CUV 0.41% $14.64 clinuvel pharmaceuticals limited

“We expect the first results in 2021 and will monitor the safety...

  1. 790 Posts.
    lightbulb Created with Sketch. 1016
    “We expect the first results in 2021 and will monitor the safety of the XP patients receiving SCENESSE® day to day. It is
    of high relevance to confirm the role of SCENESSE® in UV radiation damage regeneration and will improve the general
    understanding how to reduce skin cancer risk for many of us,” Dr Bilbao said.

    A couple of big things in that last paragraph. One is results are very close - next year - as a lot of boxes have been ticked off here already by existing data that has been captured. Second is about reducing the risk of skin cancer which is a MAJOR health problem - so treatment for a much more prevalent and also terrible disease to follow???
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.64
Change
0.060(0.41%)
Mkt cap ! $731.6M
Open High Low Value Volume
$14.61 $14.99 $14.40 $618.1K 42.38K

Buyers (Bids)

No. Vol. Price($)
9 391 $14.60
 

Sellers (Offers)

Price($) Vol. No.
$14.64 372 11
View Market Depth
Last trade - 12.00pm 10/07/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.